Preclinical studies of [68]Ga-DOTATOC: biodistribution assessment in Syrian rats and evaluation of absorbed dose in human organs
Asia Oceania Journal of Nuclear Medicine and Biology. 2016; 4 (1): 19-29
Dans Anglais
| IMEMR
| ID: emr-176188
ABSTRACT
Objective[s] Gallium-68 DOTA-DPhe[1]-Tyr[3]-Octreotide [[68]Ga-DOTATOC] has been applied by several European centers for the treatment of a variety of human malignancies. Nevertheless, definitive dosimetric data are yet unavailable. According to the Society of Nuclear Medicine and Molecular Imaging, researchers are investigating the safety and efficacy of this radiotracer to meet Food and Drug Administration requirements. The aim of this study was to introduce the optimized procedure for [68]Ga-DOTATOC preparation, using a novel germanium-68 [[68]Ge]/[68]Ga generator in Iran and evaluate the absorbed doses in numerous organs with high accuracy
Recherche sur Google
Indice:
Méditerranée orientale
Sujet Principal:
Composés organométalliques
/
Rats
/
Octréotide
/
Récepteur somatostatine
Limites du sujet:
Animaux
langue:
Anglais
Texte intégral:
Asia Oceania J. Nucl. Med. Biol.
Année:
2016
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS